Amgen Inc. (NASDAQ:AMGN) is one of the best value stocks in Goldman Sachs’ portfolio. On September 18, Piper Sandler analyst David Amsellem maintained a Buy rating on Amgen and with an unchanged price target of $342. A few weeks before this update, William Blair analyst Matt Phipps, who also rates the stock a Buy, highlighted the importance of the company’s upcoming FORTITUDE-102 study results, which combine bemarituzumab with chemotherapy and Opdivo. A favorable outcome for this study could substantially ...